Epinephrine - Revision history

Danbot: Switch SMW query from broadtable to table format for better layout with TOC

2026-03-20T21:55:17Z

Switch SMW query from broadtable to table format for better layout with TOC

2026-03-20T17:23:45Z

Fix SMW query: replace link=subject with mainlabel=- to fix broken subobject fragment links

2026-03-20T16:40:52Z

Replace static Indications section with dynamic SMW query table pulling dosing from all disease pages

← Older revision		Revision as of 16:40, 20 March 2026
Line 93:		Line 93:
	**However clinical trials have not demonstrated worsened outcomes		**However clinical trials have not demonstrated worsened outcomes

	==Indications==		==Indications by Condition==
	*Epi versus norepi in patients with shock found that elevated levels of lactic acidosis or tachycardia in 13% of epi patients causes <ref> https:/~~/www~~.~~ncbi.nlm.nih.gov/pubmed/18654759 </ref>~~		''The following table is automatically generated from disease/condition pages across WikEM.''
	*Second-line agent in sepsis that should be considered after shock is refractory to other [[~~vasopressors~~]] ~~2/2 increased number of adverse events that include tachydysrhythmias and lactate production~~
			{{#ask:[[Has DrugName::Epinephrine]]
			\|?Has Indication=Indication
			\|?Has Dose=Dose
			\|?Has Context=Context
			\|?Has Route=Route
			\|?Has Population=Population
			\|format=broadtable
			\|headers=plain
			\|link=subject
			\|sort=Has Indication
			\|limit=50
			}}

	==See Also==		==See Also==

2025-07-25T16:01:32Z

← Older revision		Revision as of 16:01, 25 July 2025
Line 1:		Line 1:
	''See [[critical care quick reference]] for drug doses by weight.''		''See [[critical care quick reference]] for drug doses by weight.''
	==General==		==General==
	*Type: [[Vasopressors]]		*Type: [[Is DrugClass::Vasopressors]]
	*Dosage Forms:		*Dosage Forms:
	*Concentration		*Concentration

2023-08-14T19:40:19Z

Pharmacology

← Older revision		Revision as of 19:40, 14 August 2023
Line 67:		Line 67:
	==Pharmacology==		==Pharmacology==
	*Onset of action: 1-2 minutes (IV), 8-10 minutes (IM)		*Onset of action: 1-2 minutes (IV), 8-10 minutes (IM)
	*Half-life: < 5 minutes (IV)<ref>Dalal R, Grujic D. Epinephrine. [Updated 2022 May 8]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK482160/</ref>		*Half-life: < 5 minutes (IV)<ref>Dalal R, Grujic D. Epinephrine. [Updated 2022 May 8]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK482160/</ref>, 45 minutes (IM)
	*Metabolism: Hepatic		*Metabolism: Hepatic
	*Excretion: Renal		*Excretion: Renal

2023-08-14T19:39:52Z

Pharmacology

← Older revision		Revision as of 19:39, 14 August 2023
Line 66:		Line 66:

	==Pharmacology==		==Pharmacology==
	*Half-life: < 5 minutes (~~when given~~ IV)<ref>Dalal R, Grujic D. Epinephrine. [Updated 2022 May 8]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK482160/</ref>		*Onset of action: 1-2 minutes (IV), 8-10 minutes (IM)
			*Half-life: < 5 minutes (IV)<ref>Dalal R, Grujic D. Epinephrine. [Updated 2022 May 8]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK482160/</ref>
	*Metabolism: Hepatic		*Metabolism: Hepatic
	*Excretion: Renal		*Excretion: Renal

2022-09-30T19:00:42Z

Pharmacology

← Older revision		Revision as of 19:00, 30 September 2022
Line 66:		Line 66:

	==Pharmacology==		==Pharmacology==
	*Half-life:		*Half-life: < 5 minutes (when given IV)<ref>Dalal R, Grujic D. Epinephrine. [Updated 2022 May 8]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK482160/</ref>
	*Metabolism: Hepatic		*Metabolism: Hepatic
	*Excretion: Renal		*Excretion: Renal
	*Mechanism of action: potent α and β agonist that increases cardiac output and peripheral vascular resistance		*Mechanism of action: potent α and β agonist that increases cardiac output and peripheral vascular resistance

	==Mechanism of Action==		==Mechanism of Action==

2022-01-04T10:24:20Z

Indications

← Older revision		Revision as of 10:24, 4 January 2022
Line 94:		Line 94:
	==Indications==		==Indications==
	*Epi versus norepi in patients with shock found that elevated levels of lactic acidosis or tachycardia in 13% of epi patients causes <ref> https://www.ncbi.nlm.nih.gov/pubmed/18654759 </ref>		*Epi versus norepi in patients with shock found that elevated levels of lactic acidosis or tachycardia in 13% of epi patients causes <ref> https://www.ncbi.nlm.nih.gov/pubmed/18654759 </ref>
	*~~second~~- line agent in sepsis that should be considered after shock is refractory to other ~~pressors~~ 2/2 increased number of adverse events that include tachydysrhythmias and lactate production		*Second-line agent in sepsis that should be considered after shock is refractory to other [[vasopressors]] 2/2 increased number of adverse events that include tachydysrhythmias and lactate production

	==See Also==		==See Also==

2022-01-04T10:23:04Z

Dose-dependent effects

← Older revision		Revision as of 10:23, 4 January 2022
Line 84:		Line 84:

	===Dose-dependent effects===		===Dose-dependent effects===
	*1-10 mcg/min - increase HR and SV		*1-10 mcg/min - increase HR and SV ("inotropic" epinephrine)
	*10-20 mcg/min - increase SVR		*10-20 mcg/min - increase SVR

	==Notes==		==Notes==

2022-01-04T10:22:20Z

Cardiac Arrest